Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer Hirotaka IwaseShunzo KobayashiAkira Masaoka Report Pages: 215 - 221
Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue C. RosenquistS. M. ThorpeJ. Grøndahl-Hansen Report Pages: 223 - 229
Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy Masahiro WatataniKoichi NagayamaMasayuki Yasutomi Report Pages: 231 - 239
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer S. R. D. JohnstonB. P. HaynesM. Dowsett Report Pages: 241 - 250
Establishment and characterization of a new cell line from primary human breast carcinoma Dino AmadoriLivia BertoniWainer Zoli Report Pages: 251 - 260
Concurrent abnormal expression of ERBB-2, EGFR, and p53 genes and clinical disease progression of breast carcinoma Daniel W. VisscherRudolph CastellaniMohamed E. Hussain Report Pages: 261 - 266
Finite proliferative lifespanin vitro of a human breast cancer cell strain isolated from a metastatic lymph node Michael L. MahacekDavid G. BeerStephen P. Ethier Report Pages: 267 - 276
Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer Deborah K. ArmstrongJohn H. FettingMartin D. Abeloff Report Pages: 277 - 284
Fifth International Workshop on Breast Cancer Research and Immunology San Francisco, November 16–17, 1992 Orlando Santos Meeting report Pages: 285 - 290
Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer Stephanie F. WilliamsSusan E. MyersJacob D. Bitran Brief communication Pages: 291 - 294
Expression of the pS2 gene in normal breast tissue Erika HähnelPeter RobbinsRoland Hähnel Brief communication Pages: 295 - 297
Comment on ‘Predicting recurrence in axillary node negative breast cancer patients’, by Rosner and Lane MH GaleaRW Blamey Correspondence Pages: 299 - 300